- Home
- ALV vs CORT Comparison
ALV vs CORT Comparison
Compare ALV & CORT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALV
- CORT
- Stock Information
- Founded
- ALV 1953
- CORT 1998
- Country
- ALV Sweden
- CORT United States
- Employees
- ALV N/A
- CORT N/A
- Industry
- ALV Auto Parts:O.E.M.
- CORT Biotechnology: Pharmaceutical Preparations
- Sector
- ALV Consumer Discretionary
- CORT Health Care
- Exchange
- ALV Nasdaq
- CORT Nasdaq
- Market Cap
- ALV 9.7B
- CORT 7.6B
- IPO Year
- ALV 1997
- CORT N/A
- Fundamental
- Price
- ALV $124.86
- CORT $75.22
- Analyst Decision
- ALV Buy
- CORT Strong Buy
- Analyst Count
- ALV 9
- CORT 4
- Target Price
- ALV $125.22
- CORT $139.00
- AVG Volume (30 Days)
- ALV 504.2K
- CORT 675.5K
- Earning Date
- ALV 10-17-2025
- CORT 10-29-2025
- Dividend Yield
- ALV 2.72%
- CORT N/A
- EPS Growth
- ALV 21.77
- CORT N/A
- EPS
- ALV 9.16
- CORT 1.11
- Revenue
- ALV $10,462,000,000.00
- CORT $716,080,000.00
- Revenue This Year
- ALV $3.64
- CORT $30.62
- Revenue Next Year
- ALV $4.06
- CORT $37.68
- P/E Ratio
- ALV $13.65
- CORT $67.23
- Revenue Growth
- ALV N/A
- CORT 25.71
- 52 Week Low
- ALV $75.49
- CORT $38.68
- 52 Week High
- ALV $127.89
- CORT $117.33
- Technical
- Relative Strength Index (RSI)
- ALV 57.63
- CORT 60.68
- Support Level
- ALV $124.26
- CORT $69.03
- Resistance Level
- ALV $127.77
- CORT $74.79
- Average True Range (ATR)
- ALV 2.04
- CORT 2.69
- MACD
- ALV -0.36
- CORT 0.32
- Stochastic Oscillator
- ALV 49.57
- CORT 95.62
About ALV Autoliv Inc.
Autoliv Inc is the world-wide leader in passive safety components and systems for the auto industry. Products include seat belts, frontal air bags, side-impact air bags, air bag inflators, and steering wheels. The Renault-Nissan-Mitsubishi alliance is the company's largest customer at 10% of 2023 revenue, with Stellantis accounting for 10% and Volkswagen 9%. At 34% of 2023 revenue, the Americas was Autoliv's largest geographic region, followed by Europe at 27%, China at 20%, and rest of world at 19%.
About CORT Corcept Therapeutics Incorporated
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic and neuropsychiatric disorders by modulating the effect of the hormone cortisol. The company's compounds are being evaluated in clinical trials as potential treatments for a variety of serious disorders - hypercortisolism, advanced ovarian cancer, prostate cancer, ALS, and MASH.